Research graph
References from Re: Pierre-Etienne Gabriel, Alec Zhu, Paolo Gontero, Morgan Rouprêt, Evanguelos Xylinas, John P Sfakianos. BCG-unresponsive NMIBC: An Obsolete Definition in a Multimodal and Evolving Therapeutic Landscape. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.028. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.eururo.2026.03.028
10.1016/j.eururo.2026.03.028 · External reference
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial
10.1038/s41591-025-03738-z · 2025 · External reference
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
10.1016/s0140-6736(25)01897-5 · 2025 · External reference
SWOG S1602: a phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660)
10.1200/jco.2026.44.7_suppl.lba629 · 2026 · External reference
